TailorMed Showcases Innovative Patient-Facing Solution at Becker’s Fall Chief Pharmacy Officer Summit

2 months ago

TailorMed Connect Gives Patients Direct Access to Critical Support While Scaling Health Systems' Impact NEW YORK, NY / ACCESS Newswire…

Standard Dental Labs Signs Binding Agreement to Acquire Dream Dentistry Labs, LLC, Strengthening Central Florida Operations

2 months ago

ORLANDO, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” or the “Company”) today announced…

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

2 months ago

Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30…

Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. 

2 months ago

Harel Gadot, President and CEO, Microbot Medical Announces LIBERTY® Limited Market Release Company Completes the Required Infrastructure to Support the…

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

2 months ago

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline…

Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors

2 months ago

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or…

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

2 months ago

Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology…

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

2 months ago

This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a…

Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

2 months ago

TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)…

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

2 months ago

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented…